-
1
-
-
34250772381
-
-
Last accessed February 28, 2008
-
National Diabetes Surveillance System. www.cdc.gov/diabetes/ statistics/prev/national/figpersons.htm. Last accessed February 28, 2008.
-
National Diabetes Surveillance System
-
-
-
2
-
-
33845341470
-
Impact of recent increase in incidence on future diabetes burden: US, 2005-2050
-
Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: US, 2005-2050. Diabetes Care 2006, 29:2114-2116.
-
(2006)
Diabetes Care
, vol.29
, pp. 2114-2116
-
-
Narayan, K.M.1
Boyle, J.P.2
Geiss, L.S.3
Saaddine, J.B.4
Thompson, T.J.5
-
3
-
-
33845996154
-
Standards of medical care in diabetes - 2007
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30(suppl 1):S4-S41.
-
(2007)
Diabetes Care
, vol.30
, Issue.SUPPL. 1
-
-
-
4
-
-
0347133334
-
Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
-
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291:335-342.
-
(2004)
JAMA
, vol.291
, pp. 335-342
-
-
Saydah, S.H.1
Fradkin, J.2
Cowie, C.C.3
-
5
-
-
3042714557
-
The burden of treatment failure in type 2 diabetes
-
Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004, 27:1535-1540.
-
(2004)
Diabetes Care
, vol.27
, pp. 1535-1540
-
-
Brown, J.B.1
Nichols, G.A.2
Perry, A.3
-
6
-
-
33845340507
-
Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis
-
Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29:2137-2139.
-
(2006)
Diabetes Care
, vol.29
, pp. 2137-2139
-
-
Bloomgarden, Z.T.1
Dodis, R.2
Viscoli, C.M.3
Holmboe, E.S.4
Inzucchi, S.E.5
-
7
-
-
0022617246
-
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
-
Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29:46-52.
-
(1986)
Diabetologia
, vol.29
, pp. 46-52
-
-
Nauck, M.1
Stockmann, F.2
Ebert, R.3
Creutzfeldt, W.4
-
8
-
-
0141446228
-
Enhancing incretin action for the treatment of type 2 diabetes
-
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26:2929-2940.
-
(2003)
Diabetes Care
, vol.26
, pp. 2929-2940
-
-
Drucker, D.J.1
-
9
-
-
33845408977
-
Gut hormones and related concepts
-
Bloomgarden ZT. Gut hormones and related concepts. Diabetes Care 2006; 29:2319-2324.
-
(2006)
Diabetes Care
, vol.29
, pp. 2319-2324
-
-
Bloomgarden, Z.T.1
-
10
-
-
0027248866
-
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
-
Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:741-744.
-
(1993)
Diabetologia
, vol.36
, pp. 741-744
-
-
Nauck, M.A.1
Kleine, N.2
Orskov, C.3
-
11
-
-
18144401971
-
Effects of exenatide (exendin-A) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-A) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-1100.
-
(2005)
Diabetes Care
, vol.28
, pp. 1092-1100
-
-
DeFronzo, R.A.1
Ratner, R.E.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
12
-
-
0028803336
-
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
-
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44:1126-1131.
-
(1995)
Diabetes
, vol.44
, pp. 1126-1131
-
-
Deacon, C.F.1
Nauck, M.A.2
Toft-Nielsen, M.3
Pridal, L.4
Willms, B.5
Holst, J.J.6
-
13
-
-
17844399596
-
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-4 inhibitors
-
Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-4 inhibitors. Diabetologia 2005; 48:612-615.
-
(2005)
Diabetologia
, vol.48
, pp. 612-615
-
-
Holst, J.J.1
Deacon, C.F.2
-
14
-
-
0033303516
-
Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
-
Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140:5356-5363.
-
(1999)
Endocrinology
, vol.140
, pp. 5356-5363
-
-
Hansen, L.1
Deacon, C.F.2
Orskov, C.3
Holst, J.J.4
-
15
-
-
33847072735
-
-
Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagen-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl pieptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56:8-15.
-
Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagen-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl pieptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56:8-15.
-
-
-
-
16
-
-
33748331194
-
Chronic-inhibition of dipeptidyl peptidase IV with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
-
Mu J, Woods J, Zhou YP, et al. Chronic-inhibition of dipeptidyl peptidase IV with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55:1695-1704.
-
(2006)
Diabetes
, vol.55
, pp. 1695-1704
-
-
Mu, J.1
Woods, J.2
Zhou, Y.P.3
-
17
-
-
0037342614
-
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-Induced diabetic rats
-
Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-Induced diabetic rats. Diabetes 2003; 52:741-750.
-
(2003)
Diabetes
, vol.52
, pp. 741-750
-
-
Pospisilik, J.A.1
Martin, J.2
Doty, T.3
-
18
-
-
33749871472
-
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabites
-
Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabites. J Clin Endocrinol Metab 2006; 91:4612-4619.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 4612-4619
-
-
Herman, G.A.1
Bergman, A.2
Stevens, C.3
-
19
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29:2632-2637.
-
(2006)
Diabetes Care
, vol.29
, pp. 2632-2637
-
-
Aschner, P.1
Kipnes, M.S.2
Lunceford, J.K.3
Sanchez, M.4
Mickel, C.5
Williams-Herman, D.E.6
-
20
-
-
33845489598
-
-
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D. Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564-2571.
-
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D. Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49:2564-2571.
-
-
-
-
21
-
-
33846796143
-
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes
-
Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:186-193.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 186-193
-
-
Brazg, R.1
Xu, L.2
Dalla Man, C.3
Cobelli, C.4
Thomas, K.5
Stein, P.P.6
-
22
-
-
33845476757
-
Efficacy and safety of the clipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the clipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638-2643.
-
(2006)
Diabetes Care
, vol.29
, pp. 2638-2643
-
-
Charbonnel, B.1
Karasik, A.2
Liu, J.3
Wu, M.4
Meininger, G.5
-
23
-
-
33751557143
-
-
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, Placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-1568.
-
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, Placebo-controlled, parallel-group study. Clin Ther 2006; 28:1556-1568.
-
-
-
-
24
-
-
33847024333
-
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
-
Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61:171-180.
-
(2007)
Int J Clin Pract
, vol.61
, pp. 171-180
-
-
Scott, R.1
Wu, M.2
Sanchez, M.3
Stein, P.4
-
25
-
-
33846817233
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial
-
Nauck MA, Meininger JG, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9:194-205.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 194-205
-
-
Nauck, M.A.1
Meininger, J.G.2
Sheng, D.3
Terranella, L.4
Stein, P.P.5
-
26
-
-
85036946660
-
-
Scott RS, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes and renal insufficiency [abtract]. Diabetes 2006; 55(suppi 1):A462.
-
Scott RS, Hartley P, Luo E, et al. Use of sitagliptin in patients with type 2 diabetes and renal insufficiency [abtract]. Diabetes 2006; 55(suppi 1):A462.
-
-
-
-
27
-
-
84882255983
-
-
Last accessed February 28, 2008
-
Januvia prescribing information. www.merck.com/product/usa/ pi_circulars/j/products_j.html. Last accessed February 28, 2008.
-
Januvia prescribing information
-
-
-
28
-
-
27744540889
-
Improved glycaemic control with dipeptidyl-peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
-
Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl-peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7:692-698.
-
(2005)
Diabetes Obes Metab
, vol.7
, pp. 692-698
-
-
Ristic, S.1
Byiers, S.2
Foley, J.3
Holmes, D.4
-
29
-
-
33751081470
-
Effect of vildagliptin on drug-naïve patients with type 2 diabetes
-
Dejager S, Baron M, Razac S, Foley JE, Dickinson S, Schweizer S. Effect of vildagliptin on drug-naïve patients with type 2 diabetes. Diabetologia 2006; 49(suppl 1):479-480.
-
(2006)
Diabetologia
, vol.49
, Issue.SUPPL. 1
, pp. 479-480
-
-
Dejager, S.1
Baron, M.2
Razac, S.3
Foley, J.E.4
Dickinson, S.5
Schweizer, S.6
-
30
-
-
9444285818
-
Twelve- and 52-week efficacy of the dipeptidyl peptidase iv inhibitor laf237 in metformin-treated patients with type 2 diabetes
-
Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase iv inhibitor laf237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2874-2880.
-
(2004)
Diabetes Care
, vol.27
, pp. 2874-2880
-
-
Ahrén, B.1
Gomis, R.2
Standl, E.3
Mills, D.4
Schweizer, A.5
-
31
-
-
34147093268
-
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
-
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30:890-895.
-
(2007)
Diabetes Care
, vol.30
, pp. 890-895
-
-
Bosi, E.1
Camisasca, R.P.2
Collober, C.3
Rochotte, E.4
Garber, A.J.5
-
32
-
-
33846828660
-
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study
-
Garber A, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9:166-174.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 166-174
-
-
Garber, A.1
Schweizer, A.2
Baron, M.A.3
Rochotte, E.4
Dejager, S.5
-
33
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50:1148-1155.
-
(2007)
Diabetologia
, vol.50
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
34
-
-
33748316958
-
Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM) [abstract]
-
Dejager S, LeBeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006; 55(suppl 1):A29.
-
(2006)
Diabetes
, vol.55
, Issue.SUPPL. 1
-
-
Dejager, S.1
LeBeaut, A.2
Couturier, A.3
Schweizer, A.4
-
35
-
-
33846694046
-
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes
-
Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007; 30:217-223.
-
(2007)
Diabetes Care
, vol.30
, pp. 217-223
-
-
Rosenstock, J.1
Baron, M.A.2
Dejager, S.3
Mills, D.4
Schweizer, A.5
-
36
-
-
33846827085
-
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
-
Rosenstock J, Baron MA, Camisasca R-P, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:175-185.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 175-185
-
-
Rosenstock, J.1
Baron, M.A.2
Camisasca, R.-P.3
Cressier, F.4
Couturier, A.5
Dejager, S.6
|